Mission Statement, Vision, & Core Values (2026) of Boai NKY Medical Holdings Ltd.

Boai NKY Medical Holdings Ltd. (listed on the Shenzhen Stock Exchange as 300109.SZ) stands at the intersection of fine chemicals and precision medicine, leveraging a legacy of over 38 years in PVP industrialization and an annual production capacity of 35,000 tons to serve over 50 countries and regions, while pursuing a mission to serve customers, empower employees, reward shareholders and benefit society; the company's strategic vision - backed by three R&D centers in Boai, Tianjin and Shanghai and a pledge to the United Nations Global Compact (joined June 2024) - commits to ambitious targets such as allocating 15% of annual revenue to research and development and aligning sustainability goals with a planned carbon reduction and patient-focused metrics, all underpinned by core values of integrity, innovation, quality, collaboration and responsibility that guide operations across a business with RMB 4.5 billion in total assets and a workforce of 1,165 as of Q1 2025

Boai NKY Medical Holdings Ltd. (300109.SZ) - Intro

• Established: 2003 (listed on SZSE, code 300109)
• PVP industrialization experience: 38+ years
• Annual PVP production capacity: 35,000 tons
• Market reach: products sold in over 50 countries and regions
• R&D sites: Boai, Tianjin, Shanghai
• Corporate pledge: joined United Nations Global Compact (June 2024)
• As of Q1 2025: 1,165 employees; total assets ≈ RMB 4.5 billion

Mission

• Deliver safe, high‑quality fine chemical materials and precision diagnostic solutions that enable better patient outcomes and empower pharmaceutical innovation.
• Advance accessible, sustainable healthcare by integrating manufacturing excellence with targeted biomedical R&D.

Vision

• Be a global leader in specialty polymers and a trusted partner in precision medicine, driving innovation from materials to diagnostics and therapeutics.
• Create long‑term value for patients, partners, employees, shareholders, and society through responsible growth and scientific leadership.

Core Values

• Quality & Safety - uncompromising product and process standards across manufacturing and diagnostics.
• Innovation - sustained investment in R&D and collaboration to translate science into clinical and industrial solutions.
• Integrity & Compliance - adherence to ethical, legal and environmental responsibilities (aligned with UN Global Compact principles).
• Customer Focus - long‑term partnerships, tailored solutions, and service excellence for global clients.
• People Centricity - talent development, workplace safety, and inclusive practices to retain and grow expertise.

Strategic Pillars & Operational Priorities

• Scale & Efficiency - optimize the 35,000‑ton PVP capacity and downstream product lines to secure margins and supply reliability.
• R&D Leadership - strengthen three R&D hubs (Boai, Tianjin, Shanghai) to accelerate polymer innovation and diagnostic assay pipelines.
• Precision Medicine Expansion - expand in vitro diagnostics portfolio and selectively invest in oncology drug candidates to build a diversified healthcare platform.
• Sustainability & Governance - implement UN Global Compact commitments (human rights, labor, environment, anti‑corruption) across operations.
• Global Market Development - deepen presence in existing 50+ countries and target growth in high‑value markets via regulatory approvals and partnerships.

Key Business Segments - Snapshot

Financial & Operational Metrics (Selected)

• Total assets (Q1 2025): ≈ RMB 4.5 billion
• Headcount (Q1 2025): 1,165 employees
• Manufacturing capacity: 35,000 tons/year PVP
• Geographic reach: products sold in >50 countries/regions
• Corporate responsibility: Joined UN Global Compact - June 2024

Boai NKY Medical Holdings Ltd. (300109.SZ) - Overview

• Customer focus: high-quality medical consumables (infusion sets, catheters, infusion pumps) and hospital consumables distributed across China and exported to multiple regions.
• Employee success: talent development programs, in-house R&D teams, and performance-linked incentives to retain technical and clinical staff.
• Shareholder returns: steady dividend policy and reinvestment into higher-margin specialty segments to drive EPS growth.
• Societal benefit: product safety, accessibility initiatives, and community health programs to improve care delivery and public health outcomes.

• Product quality and safety: ISO and CE certifications, stringent QC to serve clinical customers and comply with hospital procurement standards.
• Innovation-led growth: targeted R&D spend to move from commodity consumables to higher-value catheter and infusion system solutions.
• Talent and culture: structured career tracks, technical training, and cross-functional teams to drive employee success and operational excellence.
• Capital allocation: balancing dividends and capex-investing in automation and capacity expansion to sustain margins while delivering shareholder returns.
• Social responsibility: donation programs, subsidized supplies for community clinics, and compliance with environmental regulations in production.

• Board oversight links executive compensation to both financial targets and ESG indicators, reinforcing the mission's balance between profit and public good.
• Strategic M&A and partnerships prioritize technologies that improve clinical outcomes and broaden access to care.
• Capital investments focus on automation (to improve quality and reduce costs) and on expanding clinical-service capabilities for integrated solutions.

Boai NKY Medical Holdings Ltd. (300109.SZ) - Mission Statement

Boai NKY Medical Holdings Ltd. (300109.SZ) commits to advancing global healthcare through innovation in medical technology, patient-centered care, and sustainable operations. The mission centers on delivering high-quality diagnostic and therapeutic solutions while expanding global partnerships and investing substantially in research and development.

• Deliver reliable, clinically validated medical devices and consumables that improve patient outcomes across hospitals and clinics worldwide.
• Prioritize patient safety and satisfaction by integrating user-centric design and robust post-market support.
• Invest in R&D to accelerate breakthroughs in biotechnology, in-vitro diagnostics, and digital health.
• Adopt sustainable practices to minimize environmental impact across manufacturing and supply chains.
• Foster strategic global partnerships to broaden market access and co-develop advanced healthcare solutions.

Vision Statement

Boai NKY Group aspires to be a leader in the global healthcare sector, focusing on innovation and excellence in medical technology. The vision includes measurable sustainability, patient-centric targets, and bold R&D commitments:

• Reduce carbon footprint by 30% by 2025 (baseline: FY2020 emissions).
• Achieve patient satisfaction scores above 90% by 2024 across core product lines and service channels.
• Allocate 15% of annual revenue to R&D by 2024 to accelerate advances in biotechnology and medical devices.
• Establish strategic partnerships with leading global healthcare institutions to enhance product offerings and market reach.
• Scale production and distribution to serve an increasing global installed base while maintaining regulatory compliance and quality standards.

Strategic Priorities to Fulfill the Vision

• R&D Acceleration - dedicate 15% of revenue to core research, clinical trials, and product validation to shorten time-to-market for high-impact devices.
• Sustainability Initiatives - implement energy efficiency projects, green procurement, and logistics optimization to achieve the 30% CO2 reduction target.
• Patient Experience Programs - standardize feedback loops, clinical training, and customer support escalation to reach >90% satisfaction.
• Partnership & Market Expansion - pursue alliances with top-tier hospitals, research institutes, and regional distributors to increase adoption and co-development opportunities.

For an in-depth look at company background, mission evolution, ownership and how Boai NKY operates financially, see: Boai NKY Medical Holdings Ltd.: History, Ownership, Mission, How It Works & Makes Money

Boai NKY Medical Holdings Ltd. (300109.SZ) - Vision Statement

• Integrity: Upholding rigorous ethical standards and full transparency in clinical data, regulatory compliance, and financial reporting.
• Innovation: Sustained investment in R&D to expand product pipelines in interventional cardiology, vascular surgery, and related devices.
• Quality: Implementing industry-leading quality management systems to ensure product safety and effectiveness from design through post-market surveillance.
• Collaboration: Building partnerships with hospitals, academic centers, and global distributors to accelerate clinical adoption and iterate on device design.
• Responsibility: Committing to community health programs, environmental stewardship, and responsible governance.

• Clinical pipeline focus: coronary and peripheral vascular devices, interventional accessories, and procedural systems.
• Quality systems: ISO 13485 certification, GMP-compliant manufacturing, and active vigilance programs for adverse event monitoring.
• Partnership model: joint clinical programs with tertiary hospitals, OEM partnerships, and distribution agreements to accelerate reach.